Clairity Breast becomes the first FDA-authorized AI software to predict five-year breast cancer risk using routine mammography images.
Key Details
- 1FDA grants de novo authorization to Clairity Breast, developed by Boston-based Clairity.
- 2The AI tool analyzes mammogram images for subtle features correlated with future cancer risk.
- 3Unlike traditional models, Clairity Breast does not require age or genetic data.
- 4The system was trained on millions of mammogram images linked to five-year outcomes.
- 5Clairity Breast delivers validated risk scores to radiologists through standard clinical systems.
- 6Commercial launch is targeted for the end of 2025.
Why It Matters
This breakthrough FDA authorization marks a new era in preventive oncology by enabling earlier risk identification using only imaging, potentially improving precision prevention and patient outcomes in breast cancer care.
Source
Radiology Business
Related News
•Radiology Business
GE HealthCare and RadNet Expand Global AI Mammography Partnership
GE HealthCare and RadNet are extending their partnership globally to offer AI-enhanced mammography systems.
•Radiology Business
NCCN Endorses AI Risk Tools for Breast Cancer Screening
NCCN's 2026 guidelines recommend routine integration of AI-based 5-year breast cancer risk prediction from mammograms.
•AuntMinnie
FDA Rejects Petition to Exempt Radiology AI Devices from 510(k) Review
FDA denies a petition to exempt certain radiology AI software from 510(k) review, stressing ongoing regulatory oversight.